Parenteral Delivery of Peptides and Proteins - Challenges in Delivery of Therapeutic Genomics and Proteomics - page 611

[397] Enzon to present at BMO capital markets focus on healthcare conference. (Nov. 2007).
http:// www.enzon.com/index.php?id 72&searchedAdagen&highlightajaxSearch_
highlightajaxSearch_highlight1. Accessed May 2009.
[398] Groves MJ, Alkan MH, Hickey AJ. The formulation of proteins and peptides. In:
Klegerman ME, Groves MJ, editors. Pharmaceutical biotechnology: fundamentals and
essentials. Buffalo Grove, NY: Interpharm Press; 1992. p. 218-48.
[399] Bukowski RM, Tendler C, Cutler D, Rose E, Laughlin MM, Statkevich P. Treating can-
cer with PEG Intron: pharmacokinetic profile and dosing guidelines for an improved
interferon--2ß formulation. Cancer 2002;95:389-96.
[400] Wang YS, Youngster S, Grace M, Bausch J, Bordens R, Wyss DF. Structural and bio-
logical characterization of pegylated recombinant interferon -2b and its therapeutic
implications. Adv Drug Deliv Rev 2002;54:547-70.
[401] Press Report (Feb. 2005). Phase 3 study published in The Journal of Clinical Oncology
shows first-cycle administration of neulasta significantly lowers incidence of neutrope-
nia with related fever and hospitalization. http:// www.imunex.com/media/media_pr_
detail.jsp?year 2005&releaseID679209. Accessed May 2010.
[402] Bailon P, Palleroni A, Schaffer CA, Spence CL, Fung WJ, Porter JE, et al. Rational
design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene gly-
col-conjugated interferon -2a for the treatment of hepatitis C. Bioconjug Chem 2001;12:
195-202.
[403] FDA approves Macugen (pegaptanib sodium) for treatment of neovascular (wet) age-
related macular degeneration. Dec. 2004. http:// www.docguide.com/news/content.nsf/
news/8525697700573E1885256F70005E7A3B . Accessed May 2010.
[404] Micera: methoxy polyethylene glycol epoetinbeta; continuous activity, targeted stability.
http:// www.mircera.com/portal/mircera . Accessed May 2010.
[405] Somavert, Pegvisomant for injection. http:// www.somavert.com/index.aspx . Accessed
May 2010.
[406] Fleischmann R, Vencovsky J, van Vollenhoven RF, Borenstein D, Box J, Coteur G,
et al. Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients
with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the
FAST4WARD study. Ann Rheum Dis 2009;68:805-11.
[407] Sandborn WJ, Feagan BG, Stoinov S, Honiball PJ, Rutgeerts P, Mason D, et al.
Certolizumab Pegol for the treatment of Crohn's Disease. NE J Med 2007;357:
228-38.
[408] Darlington C. PEG-sTNF-RI. Amgen. Curr Opin Invest Drugs (BioMed Cent)
2003;4:583-7.
[409] Data from phase 2 clinical trials of hematide/peginesatide presented at NKF Annual
Meeting. 2010. The Medical News . April. http:// www.news-medical.net/news/20100416/
Data-from-Phase-2-clinical-trials-of-Hematidepeginesatide-presented-at-NKF-Annual-
Meeting.aspx . Accessed May 2010.
[410] Jayson GC, Parker GJ, Mullamitha S, Valle JW, Saunders M, Broughton L, et al.
Blockade of platelet-derived growth factor receptor- by CDP860, a humanized,
PEGylated di-Fab', leads to fluid accumulation and is associated with increased tumor
vascularized volume. J Clin Oncol 2005;23:973-81.
[411] Baker DP, Lin EY, Lin K, Pellegrini M, Petter RC, Chen LL, et al. N-terminally
PEGylated human interferon--1a with improved pharmacokinetic properties and in
vivo efficacy in a melanoma angiogenesis model. Bioconjug Chem 2006;17:179-88.
[412] Maxy-G34: next-generation G-CSF for the treatment of neutropenia and acute radiation
syndrome. http:// www.maxygen.com/products-mye.php . Accessed May 2010.